Although the AMPK signaling pathway has emerged as a pivotal molecule in recent investigations exploring the association between CS and MASLD, it is noteworthy that CS exerts its influence on liver steatosis through diverse alternative pathways. Here, PRKAA2 is linked to metabolic dysfunction-associated steatotic liver disease.